FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Bhupinder Mann(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), John R. Johnson(Santa Barbara Museum of Natural History), Martin H. Cohen(United States Food and Drug Administration)
Cited by 1,351
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration
|Journal of Clinical Oncology|2004|735